Summary & Overview
HCPCS Q5124: Ranibizumab-nuna (Byooviz) Injection, 0.1 mg
HCPCS Level II code Q5124 identifies the biosimilar ranibizumab-nuna (Byooviz) in a 0.1 mg presentation for intravitreal injection. This code is significant nationally as biosimilar anti-VEGF agents expand therapeutic options for retinal diseases, with implications for utilization, payer coverage policies, and cost management across outpatient ophthalmology settings. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise overview of what Q5124 represents clinically and operationally, plus benchmarking context and policy-relevant considerations: typical sites of service for administration, common billing practices, expected reporting details, and where to look for payer coverage nuances. The publication outlines benchmarks for utilization and reimbursement approaches, summarizes recent policy updates affecting biosimilar ophthalmic injectables, and provides clinical context around intravitreal anti-VEGF therapy. Data not included in the input are noted where applicable. This piece is intended to inform revenue cycle managers, coding professionals, and policy analysts about the role and coding of ranibizumab-nuna in outpatient retinal care.
Billing Code Overview
HCPCS Level II code Q5124 represents an injection of ranibizumab-nuna, a biosimilar marketed as Byooviz, at a dose of 0.1 mg. The code covers the drug product for intravitreal injection indicated for retinal conditions treated with anti-VEGF therapy.
Service Type: Intravitreal biologic injection
Typical Site of Service: Outpatient ophthalmology clinic or ambulatory surgical center (office-based intravitreal administration)
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with neovascular (wet) age-related macular degeneration, diabetic macular edema, or retinal vein occlusion presenting to a retinal specialty clinic or ambulatory surgical center for intravitreal anti-VEGF therapy. The medication administered is Q5124 (injection, ranibizumab-nuna, biosimilar, (Byooviz), 0.1 mg). Clinical workflow: the retina specialist confirms indication and documents visual acuity, intraocular pressure, and a focused eye exam; obtains informed consent for intravitreal injection; performs pre-procedure antisepsis with povidone-iodine; may apply topical anesthesia and a lid speculum; administers the intravitreal injection of Q5124 under sterile technique; monitors the patient briefly for immediate complications; documents lot number and syringe disposal per hazardous drug rules (use of modifier JW may be applicable when reporting discarded portions of single‑use vials or syringes). Typical site of service is an ophthalmology clinic procedure room or ambulatory surgical center. The patient scenario commonly involves a planned series of injections (loading doses then maintenance) with follow-up visits for optical coherence tomography and visual acuity assessment.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW |